ERBB2 and breast carcinoma: Currently, the targeted therapeutic strategies in HER2-positive breast cancer include inhibiting HER2 dimerization by monoclonal antibodies like trastuzumab and inhibiting HER2 kinase activity with small molecule inhibitors such as lapatinib.